Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient.
Colchicine is the treatment of choice in familial Mediterranean fever (FMF) both for attacks and for prevention of secondary amyloidosis. The overall non-responder rate varies from 5-10 to 40%. Thalidomide is known to blunt the acute phase response. We report the efficacy of the addition of thalidomide to colchicine in controlling the febrile attacks and acute phase response in a patient with FMF resistant to 2 mg colchicine per day.
Seyahi
E
E
Department of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Turkey.
Ozdogan
H
H
Masatlioglu
S
S
Yazici
H
H
D003078:Colchicine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D010505:Familial Mediterranean Fever / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013792:Thalidomide / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D013792:Thalidomide; D003078:Colchicine